Literature DB >> 25058253

Use of two grading systems in determining risks associated with timing of fracture fixation.

Nickolas J Nahm1, Timothy A Moore, Heather A Vallier.   

Abstract

BACKGROUND: The early appropriate care (EAC) protocol and clinical grading system (CGS) propose criteria that suggest timing of definitive fracture fixation by assessing risk for complications. This study applies these criteria to a cohort of patients with orthopedic injuries and determines clinical outcomes for groups stratified by risk and timing of fracture fixation.
METHODS: This retrospective work was performed at a Level I trauma center. Patients with operative femur, pelvis, acetabulum, and/or thoracolumbar spine injuries were included. Fractures were treated surgically, either early or delayed. Patients were retrospectively categorized into low- or high-risk groups using the EAC protocol and described as stable, borderline, unstable, or in extremis using a modified CGS (mCGS).
RESULTS: In the EAC analysis, low-risk patients treated early had fewer complications compared with delayed treatment. Among high-risk patients, no significant difference was noted. With the use of the mCGS, stable patients treated early had fewer complications compared with delayed patients. No difference in complications was detected for unstable and in extremis patients. Borderline patients treated early had fewer complications compared with delayed treatment, although results were not supported by sensitivity analysis.
CONCLUSION: The EAC protocol can effectively distinguish patients who are at high risk for complications if treated early. Early treatment in the low-risk group was associated with fewer complications. The mCGS differentiates stable patients who benefit from early definitive treatment of fractures as well as severely injured patients (unstable or in extremis) who may benefit from damage-control orthopedics. Borderline patients may also benefit from early definitive treatment, but criteria defining borderline patients require further study. LEVEL OF EVIDENCE: Prognostic study, level III.

Entities:  

Mesh:

Year:  2014        PMID: 25058253     DOI: 10.1097/TA.0000000000000283

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  6 in total

1.  Polytrauma management - What is new and what is true in 2020 ?

Authors:  H C Pape; L Leenen
Journal:  J Clin Orthop Trauma       Date:  2020-10-29

2.  Are work return and leaves of absence after acetabular fractures predictable? : A retrospective study of 108 patients.

Authors:  A Aprato; A Joeris; F Tosto; V Kalampoki; E Rometsch; M Favuto; A Stucchi; M Azi; A Massè
Journal:  Musculoskelet Surg       Date:  2016-10-12

Review 3.  Pelvic trauma: WSES classification and guidelines.

Authors:  Federico Coccolini; Philip F Stahel; Giulia Montori; Walter Biffl; Tal M Horer; Fausto Catena; Yoram Kluger; Ernest E Moore; Andrew B Peitzman; Rao Ivatury; Raul Coimbra; Gustavo Pereira Fraga; Bruno Pereira; Sandro Rizoli; Andrew Kirkpatrick; Ari Leppaniemi; Roberto Manfredi; Stefano Magnone; Osvaldo Chiara; Leonardo Solaini; Marco Ceresoli; Niccolò Allievi; Catherine Arvieux; George Velmahos; Zsolt Balogh; Noel Naidoo; Dieter Weber; Fikri Abu-Zidan; Massimo Sartelli; Luca Ansaloni
Journal:  World J Emerg Surg       Date:  2017-01-18       Impact factor: 5.469

Review 4.  Orthopaedic traumatology: fundamental principles and current controversies for the acute care surgeon.

Authors:  Shad K Pharaon; Shawn Schoch; Lucas Marchand; Amer Mirza; John Mayberry
Journal:  Trauma Surg Acute Care Open       Date:  2018-01-08

5.  Damage control orthopaedics: State of the art.

Authors:  Enrique Guerado; Maria Luisa Bertrand; Juan Ramon Cano; Ana María Cerván; Adolfo Galán
Journal:  World J Orthop       Date:  2019-01-18

6.  How to detect a polytrauma patient at risk of complications: A validation and database analysis of four published scales.

Authors:  Sascha Halvachizadeh; Larissa Baradaran; Paolo Cinelli; Roman Pfeifer; Kai Sprengel; Hans-Christoph Pape
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.